Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer. Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope,” he told Asbestos.com. “We haven’t had anything like this for mesothelioma in a long time. I really look forward to speaking with these patients now.” Moffitt recently became the first multidisciplinary specialty center to begin enrolling mesothelioma patients in a trial that will evaluate the efficacy of combining CRS-207 with pembrolizumab — two immunotherapy drugs that already showed effectiveness individually — in a second-line setting. “Of course, the hope is that we see significant tumor shrinkage. We already know, we have data, that each of these agents will work in a number of patients,” Tanvetyanon said. “There is good reason to think that combining the two will work even better, a one-plus-one-equals-three synergy.” Drug Companies Working Together Two competing pharmaceutical companies have worked together to make this latest, anti-cancer combination a reality for mesothelioma patients. Aduro Biotech, based in Berkeley, California, produces CRS-207, which us...
ConclusionsFOSL1 is an independent prognostic biomarker of GC. Detecting FOSL1 expression could help stratify GC patients with high-risk and guide the precious treatment.
In this study, we aimed to investigate the role of IL-6/Stat3 signaling pathway in human endometrial cancer cells invasion and migration. We demonstrated that Stat3 is activated in endometrial cancer cell lines. To investigate the role of Stat3 in endometrial cancer invasive capacity, we used Stat3 inhibitor Stattic and found that Stattic significantly inhibited the migration and invasion of endometrial cancer cells elevated by IL-6. Furthermore, we showed that Stat3 inhibitor significantly decreased the expression of MMP2 enhanced by IL-6, indicating that IL-6 promoted endometrial cancer invasion and migration by Stat3-in...
Publication date: Available online 19 March 2019Source: Pathology - Research and PracticeAuthor(s): Xiaobo He, Ying ShuAbstractIncreasing evidence has shown that dysregulation of mircoRNA (miRNA) is linked to the development and progression of human cancer, including gastric cancer (GC). In the current study, by analysing the GEO database (GSE78091), we found that miR-660 was significantly downregulated in GC. Consistently, quantitative real-time PCR (qRT-PCR) results showed that miR-660 was dramatically decreased in GC tissues and cell lines. Importantly, low miR-660 expression was closely related to larger tumor size (P&...
ConclusionsThe results pointed out that the high expression of miR-106b-5p serves as an independent factor for predicting the worse prognosis of RCC patients.
Conclusions: DIM is a very rare tumour. The global survival is excellent. Conservative treatment with PT is an efficient alternative to enucleation and allows good local tumour control. Cataract and glaucoma are the main radiation-related complications, but the corneal status was excellent due to the stem cell harvest prior to radiotherapy.Ocul Oncol Pathol
Conclusion: There are no relevant differences between men and women in ocular or patient survival after brachytherapy for uveal melanoma.Ocul Oncol Pathol
Conclusions: Conjunctival melanocytic lesions suspicious for melanocytoma should be bleached to evaluate their cytologic features. CD68 can be helpful in identifying heavily pigmented melanomacrophages which may mimic a melanocytoma. As conjunctival melanocytomas are extremely rare, their pathogenesis may be different from that of other conjunctival nevi.Ocul Oncol Pathol
In conclusion, clinical presentation at time of diagnosis of brain metastases consistently includes neurologic signs and symptoms with persistent headache being the most common. Endometrial cancer patients that present with new neurologic complaints or exam findings should be evaluated for brain metastases.
We describe a case of an 80-year-old woman with ovarian metastasis of MCC six years after excision of a cutaneous MCC on the cheek.DiscussionTo our knowledge only three cases with ovarian metastasis of MCC have been described so far. Our case is the second with distant metastasis to the ovary spreading from a primary tumor in the skin of the head, in the other two cases the primary tumor was in the inguinal skin.ConculsionMCC is a highly aggressive cutaneous and mucosal malignancy with frequent recurrence, lymph node and distant metastases. There is no clear consensus how to treat metastatic disease.
In states that legalized medical marijuana, there was a 4.8 percent decrease in reported pain for conditions that qualified for pot treatment (cancer, arthritis, glaucoma and pain), compared to states without medical marijuana.